Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CID 16020046 (C390-0219) is a selective GPR55 antagonist, inhibiting GPR55 constitutive activity with IC50 of 0.15 μM in yeast.
説明 | CID 16020046 (C390-0219) is a selective GPR55 antagonist, inhibiting GPR55 constitutive activity with IC50 of 0.15 μM in yeast. |
ターゲット&IC50 | GPR55:0.15 μM |
In vitro | In yeast cells expressing human GPR55, CID16020046 inhibited agonist-induced receptor activation. In human embryonic kidney (HEK293) cells stably expressing human GPR55, CID16020046 behaved as an antagonist on LPI-mediated Ca2+ release and extracellular signal-regulated kinases activation, but not in HEK293 cells expressing cannabinoid receptor 1 or 2 (CB1 or CB2). CID16020046 dose-dependently inhibited lysophosphatidylinositol (LPI)-induced activation of nuclear factor of activated T-cells (NFAT), nuclear factor κ of activated B cells (NF-κB) and serum response element, translocation of NFAT and NF-κB, and GPR55 internalization [1]. |
別名 | C390-0219 |
分子量 | 425.44 |
分子式 | C25H19N3O4 |
CAS No. | 834903-43-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (129.28 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CID 16020046 834903-43-4 GPCR/G Protein Cannabinoid Receptor cells wound Ca2+ inhibit ERK1/2 GPR55 hERG acetylcholinesterase HEK function phosphorylation KCNH2 LPI healing endothelial platelet Inhibitor HMVEC lysophosphatidylinositol C390-0219 m-opioid G protein-coupled receptor 55 CID16020046 CID-16020046 inhibitor